Imaging changes after stereotactic body radiation therapy for lung and liver tumors

References

• Lo SS, Fakiris AJ, Chang EL et al. Stereotactic body radiation therapy: a novel treatment modality. Nat. Rev. Clin. Oncol.7(1), 44–54 (2010).
   PubMed Web of Science ®Google Scholar
• Lo SS, Fakiris AJ, Papiez L et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Expert Rev. Anticancer Ther.8(1), 87–98 (2008).
   PubMed Web of Science ®Google Scholar
• Lo SS, Fakiris AJ, Teh BS et al. Stereotactic body radiation therapy for oligometastases. Expert Rev. Anticancer Ther.9(5), 621–635 (2009).
   PubMed Web of Science ®Google Scholar
• Lo SS, Cardenes HR, Teh BS et al. Stereotactic body radiation therapy for nonpulmonary primary tumors. Expert Rev. Anticancer Ther.8(12), 1939–1951 (2008).
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood114(3), 589–595 (2009).
   PubMed Web of Science ®Google Scholar
• Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell8(2), 89–91 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science300(5622), 1155–1159 (2003).
   PubMed Web of Science ®Google Scholar
• Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur. J. Radiol. DOI: 10.1016/j.ejrad.2009.10.029 (2009) (Epub ahead of print).
   Google Scholar
• Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer69(1), 77–85 (2010).
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Heilman K, Wulf J et al. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother. Oncol.85(3), 435–442 (2007).
   PubMed Web of Science ®Google Scholar
• Takeda T, Takeda A, Kunieda E et al. Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am. J. Roentgenol.182(5), 1123–1128 (2004).
   PubMed Web of Science ®Google Scholar
• Kato S, Nambu A, Onishi H et al. Computed tomography appearances of local recurrence after stereotactic body radiation therapy for stage I non-small-cell lung carcinoma. Jpn J. Radiol.28(4), 259–265 (2010).
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Nagata Y, Mizowaki T et al. Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int. J. Clin. Oncol.12(5), 356–362 (2007).
   PubMed Web of Science ®Google Scholar
• Takeda A, Kunieda E, Takeda T et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int. J. Radiat. Oncol. Biol. Phys.70(4), 1057–1065 (2008).
   PubMed Web of Science ®Google Scholar
• Mac Manus MP, Hicks RJ, Matthews JP et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer49(1), 95–108 (2005).
   PubMed Web of Science ®Google Scholar
• Ishimori T, Saga T, Nagata Y et al.18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann. Nucl. Med.18(8), 669–674 (2004).
   PubMed Web of Science ®Google Scholar
• Hoopes DJ, Tann M, Fletcher JW et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer56(2), 229–234 (2007).
   PubMed Web of Science ®Google Scholar
• Coon D, Gokhale AS, Burton SA et al. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Clin. Lung Cancer9(4), 217–221 (2008).
   PubMed Web of Science ®Google Scholar
• Fuss M, Salter BJ, Herman TS, Thomas CR. Metabolic PET imaging for stereotactic body radiation therapy (SBRT) planning and therapy response assessment of pulmonary malignancies. Int. J. Radiat. Oncol. Biol. Phys.63(Suppl. 1), S412 (2005).
   Google Scholar
• Feigenberg S, Yu JQM, Eade TN. FDG PET response by 3 months following stereotactic body radiotherapy for non-small cell lung cancer may be an early surrogate of local failure. Int. J. Radiat. Oncol. Biol. Phys.69(3 Suppl. 1), S479–S480 (2007).
   Google Scholar
• Henderson MA, Hoopes DJ, Fletcher JW et al. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.76(3), 789–795 (2010).
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Nakamoto Y, Nagata Y et al. Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother. Oncol.97(2), 200–204 (2010).
   PubMed Web of Science ®Google Scholar
• Pan CC, Kavanagh BD, Dawson LA et al. Radiation-associated liver injury. Int. J. Radiat. Oncol. Biol. Phys.76(3 Suppl.), S94–S100 (2010).
   PubMed Web of Science ®Google Scholar
• Herfarth KK, Hof H, Bahner ML et al. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int. J. Radiat. Oncol. Biol. Phys.57(2), 444–451 (2003).
   PubMed Web of Science ®Google Scholar
• Olsen CC, Welsh J, Kavanagh BD et al. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.73(5), 1414–1424 (2009).
   PubMed Web of Science ®Google Scholar
• Price TR, Perkins SM, Sandrasegaran K et al. Evaluation of response after stereotactic body radiation therapy for hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys.75(3 Suppl.), S677–S678 (2009).
   PubMedGoogle Scholar
• Zook JE, Sandrasegaran K, Saxena R et al. Orthotopic liver transplant (OLT) following stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC): radiologic and pathologic correlation. Int. J. Radiat. Oncol. Biol. Phys.75(3 Suppl.), S285–S286 (2009).
   PubMedGoogle Scholar
• Casamassima F, Masi L, Menichelli C et al. IGRT stereotactic hypofractionated radiotherapy for treatment of focal liver malignancies. Int. J. Radiat. Oncol. Biol. Phys.72(1 Suppl. 1), S277–S278 (2008).
   Google Scholar
• Krix M, Plathow C, Essig M et al. Monitoring of liver metastases after stereotactic radiotherapy using low-MI contrast-enhanced ultrasound – initial results. Eur. Radiol.15(4), 677–684 (2005).
   PubMedGoogle Scholar
• Hof H, Zgoda J, Nill S et al. Time- and dose-dependency of radiographic normal tissue changes of the lung after stereotactic radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.77(5), 1369–1374 (2010).
   PubMedGoogle Scholar
• Rajagopalan MS, Heron DE. Role of PET/CT imaging in stereotactic body radiotherapy. Future Oncol.6(2), 305–317 (2010).
   PubMedGoogle Scholar